EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Severe bradycardia after amivantamab administration in a patient with epidermal growth factor receptor-positive non-small cell lung cancer: A case report

Shoko Kamenosono, Aki Ikeda, Hideaki Takahashi, Toshikazu Watanabe, Tetsunari Hase, Nanami Kiryu, Shin Hasegawa, Yoshiko Shigeyasu, Tomohide Souma, Tomoya Horiguchi, Yasuhiro Goto, Naozumi Hashimoto und 1 weitere

Fujita Medical Journal · 2026-08 · 12 (3) · 251-254

DOI: 10.20407/fmj.2026-003 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Fujita Medical Journal, 2026-08. Verfasst von Shoko Kamenosono und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amivantamab, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal–epithelial transition factor, has shown clinical efficacy in patients with EGFR-mutated non-small cell lung cancer. Although infusion-related reactions (IRRs) are common adverse events associated with this drug, cardiac events such as bradycardia have rarely been reported. We report the case of a 53-year-old Japanese man with advanced EGFR exon 19-deleted lung adenocarcinoma who was treated with amivantamab plus lazertinib as eighth-line therapy. On the first day, he experienced dyspnea, chills, and headache 30 min after amivantamab administration, so the infusion flow was reduced to 25 mL/h. After the symptoms resolved, the flow rate was set to 50 mL/h. On the second day, 2 h after initiating amivantamab infusion (700 mg) at 50 mL/h, his heart rate decreased to

Schlagwörter

Stichwörter der Autor:innen

AmivantamabBradycardiaInfusion-related reactionsNon-small cell lung cancer

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.

Zitieren

APA

Kamenosono, S., Ikeda, A., Takahashi, H., Watanabe, T., Hase, T., Kiryu, N., Hasegawa, S., Shigeyasu, Y., Souma, T., Horiguchi, T., Goto, Y., Hashimoto, N., & Imaizumi, K. (2026). Severe bradycardia after amivantamab administration in a patient with epidermal growth factor receptor-positive non-small cell lung cancer: A case report. Fujita Medical Journal, 12(3), 251-254. https://doi.org/10.20407/fmj.2026-003

Vancouver

Kamenosono S, Ikeda A, Takahashi H, Watanabe T, Hase T, Kiryu N, et al. Severe bradycardia after amivantamab administration in a patient with epidermal growth factor receptor-positive non-small cell lung cancer: A case report. Fujita Medical Journal. 2026;12(3):251-254. doi:10.20407/fmj.2026-003

BibTeX
@article{Kamenosono2026,
  author = {Kamenosono, Shoko and Ikeda, Aki and Takahashi, Hideaki and Watanabe, Toshikazu and Hase, Tetsunari and Kiryu, Nanami and Hasegawa, Shin and Shigeyasu, Yoshiko and Souma, Tomohide and Horiguchi, Tomoya and Goto, Yasuhiro and Hashimoto, Naozumi and Imaizumi, Kazuyoshi},
  title = {Severe bradycardia after amivantamab administration in a patient with epidermal growth factor receptor-positive non-small cell lung cancer: A case report},
  journal = {Fujita Medical Journal},
  year = {2026},
  volume = {12},
  number = {3},
  pages = {251--254},
  doi = {10.20407/fmj.2026-003}
}
Kostenlos starten →